DREADDs — Designer Receptors Exclusively Activated by Designer Drugs

<div class="infobox infobox-technology">
<div class="infobox-header">DREADDs</div>
<div class="infobox-row"><span class="infobox-label">Full Name</span><span class="infobox-value">Designer Receptors Exclusively Activated by Designer Drugs</span></div>
<div class="infobox-row"><span class="infobox-label">Category</span><span class="infobox-value">Chemogenetic Neuromodulation</span></div>
<div class="infobox-row"><span class="infobox-label">Activation Method</span><span class="infobox-value">Pharmacological (CNO, deschloroclozapine)</span></div>
<div class="infobox-row"><span class="infobox-label">Clinical Status</span><span class="infobox-value">Preclinical / Translational Research</span></div>
<div class="infobox-row"><span class="infobox-label">Applications</span><span class="infobox-value">Circuit mapping, Seizure control, Movement disorders</span></div>
</div>

Overview

<div class="infobox infobox-technology">
<div class="infobox-header">DREADDs</div>
<div class="infobox-row"><span class="infobox-label">Full Name</span><span class="infobox-value">Designer Receptors Exclusively Activated by Designer Drugs</span></div>
<div class="infobox-row"><span class="infobox-label">Category</span><span class="infobox-value">Chemogenetic Neuromodulation</span></div>
<div class="infobox-row"><span class="infobox-label">Activation Method</span><span class="infobox-value">Pharmacological (CNO, deschloroclozapine)</span></div>
<div class="infobox-row"><span class="infobox-label">Clinical Status</span><span class="infobox-value">Preclinical / Translational Research</span></div>
<div class="infobox-row"><span class="infobox-label">Applications</span><span class="infobox-value">Circuit mapping, Seizure control, Movement disorders</span></div>
</div>

Overview

Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) are a chemogenetic technology that allows precise control of neuronal activity through the administration of synthetic ligands. Originally derived from human muscarinic [acetylcholine](/entities/acetylcholine) receptors, DREADDs provide a non-invasive method to modulate specific neural circuits with high temporal and spatial precision["@roth2016"].

Unlike [optogenetics](/technologies/optogenetics), which requires genetic modification and light delivery, DREADDs can be activated systemically by administering a ligand (typically clozapine-N-oxide or deschloroclozapine), making them suitable for studies in deeper brain regions and for chronic experiments["@armbruster2007"].

Historical Development

Origin and Evolution

The DREADD technology was pioneered by Dr. Bryan Roth and colleagues at the University of North Carolina:

| Year | Milestone |
|------|-----------|
| 2007 | First generation DREADDs (hM3, hM4) developed |
| 2012 | hM3Dq and hM4Di widely adopted |
| 2015 | Cre-dependent DREADDs developed |
| 2020 | Improved ligands (DCZ, compound 21) introduced |
| 2021 | High-efficiency DREADD ligands |

Generation of DREADDs

First Generation (2007):

• hM3Dq and hM4Di derived from human muscarinic receptors
• Activated by clozapine-N-oxide (CNO)
• Limited brain penetration

• Cre-dependent expression systems
• Improved viral delivery vectors
• Application to specific cell types

• Deschloroclozapine (DCZ) — improved brain penetration
• Compound 21 — alternative high-affinity ligand
• Enhanced receptor stability

Mechanism of Action

DREADDs work through the following mechanism:

• hM3Dq activates Gq signaling → increases neuronal firing
• hM4Di activates Gi signaling → decreases neuronal firing

Receptor Variants

| DREADD | G Protein | Effect | Duration |
|--------|-----------|--------|----------|
| hM3Dq | Gq | Excitation (↑ firing) | 2-6 hours |
| hM4Di | Gi | Inhibition (↓ firing) | 2-6 hours |
| rM3D (rat) | Gs | Modulation | Variable |
| KORD | Gi | Inhibition | 4-8 hours |

Signal Transduction Pathways

hM3Dq (Excitatory):

• Activates phospholipase C (PLC)
• Increases intracellular calcium
• Depolarizes neuronal membrane
• Enhances neurotransmitter release

• Opens G protein-gated inward rectifier potassium (GIRK) channels
• Hyperpolarizes neuronal membrane
• Reduces action potential firing
• Decreases neurotransmitter release

Pharmacokinetics

| Ligand | Dose | Brain Penetration | Half-life |
|--------|------|-------------------|-----------|
| Clozapine-N-oxide (CNO) | 1-10 mg/kg | Low | 2-4 hours |
| Deschloroclozapine (DCZ) | 0.1-1 mg/kg | High | 6-12 hours |
| Compound 21 | 0.1-3 mg/kg | High | 4-8 hours |

Applications in Neurodegeneration

Parkinson's Disease

• Motor circuit modulation: DREADDs can be used to modulate the basal ganglia circuitry in PD models
• Dyskinesia research: Used to study L-DOPA-induced dyskinesias
• Therapeutic target validation: Used to test circuit hypotheses before invasive interventions
• Subthalamic nucleus modulation: Investigating STN hyperactivity in PD

Alzheimer's Disease

• Memory circuit mapping: DREADDs enable investigation of memory circuits ([hippocampus](/brain-regions/hippocampus), entorhinal cortex)
• Neuroinflammation studies: Targeting [microglia](/cell-types/microglia-neuroinflammation) for modulation of neuroinflammatory responses
• Neuronal network restoration: Testing whether modulating specific circuits can restore cognitive function[@yau2023]
• Entorhinal cortex dysfunction: Modeling early AD vulnerability

Epilepsy and Seizure Control

• Acute seizure suppression: hM4Di can suppress seizure activity in focal epilepsy models
• Chronic epilepsy: Potential for on-demand seizure control through systemic ligand administration
• Circuit-specific targeting: Modulating excitatory/inhibitory balance

ALS and Motor Neuron Disease

• Motor neuron circuit modulation: Targeting spinal cord circuits
• Respiratory circuit control: Potential for modulating brainstem respiratory centers
• Cortical hyperexcitability: Investigating mechanisms of motor neuron degeneration

Huntington's Disease

• Striatal neuron modulation: Investigating striatal dysfunction
• Motor behavior control: Testing circuit contributions to chorea
• Cognitive circuit mapping: Understanding executive dysfunction

Advantages and Limitations

Advantages

• Non-invasive activation: Systemic ligand administration reaches deep brain structures
• Long-term studies: Suitable for chronic experiments spanning weeks to months
• Cell-type specificity: Cre-dependent expression allows precise targeting
• No light requirement: No fiber implantation needed, reducing tissue damage
• Chronic implantation not required: Unlike optogenetics, no hardware remains in brain
• Dose control: Effects can be titrated by ligand dose
• Reversibility: Effects wear off as ligand clears

Limitations

• Off-target effects: Clozapine, used as a DREADD ligand, has activity at endogenous receptors
• Temporal resolution: Onset is slower than optogenetics (minutes vs. milliseconds)
• Variable expression: Viral delivery efficiency varies across brain regions
• Clinical translation: CNO does not cross the [blood-brain barrier](/entities/blood-brain-barrier) effectively; DCZ shows promise but is still preclinical[@nagai2020]
• Receptor trafficking: DREADD expression may be internalized over time
• Immune response: Potential immune reaction to foreign proteins

Comparison with Optogenetics

| Feature | DREADDs | Optogenetics |
|---------|---------|--------------|
| Temporal precision | Minutes | Milliseconds |
| Spatial precision | Cell-type specific | Cell-type specific |
| Invasiveness | Low (injection) | High (fiber implants) |
| Deep brain access | Yes | Limited by fiber length |
| Chronic studies | Excellent | Limited by fiber durability |
| Hardware requirements | None | Fiber optics, lasers |
| Clinical translation | Moderate | Challenging |

When to Use Each Technology

Use DREADDs when:

• Studying deep brain regions
• Needing chronic modulation over weeks/months
• Working with large animal models
• Combining with other surgical procedures

• Requiring millisecond precision
• Studying rapid neural dynamics
• Bidirectional control needed simultaneously
• Circuit connectivity mapping

Recent Research Developments

• Gi-DREADD for seizures: hM4Di showing efficacy in preventing seizure spread in temporal lobe epilepsy models
• hM3Dq for memory enhancement: Activation of specific hippocampal engram cells enhances memory recall in AD models
• Microglia targeting: New DREADD variants allow selective modulation of microglia for neuroinflammation studies
• KORD (Kappa opioid receptor DREADD): Alternative inhibitory DREADD using salvinorin B as ligand
• Dual DREADD systems: Simultaneous excitation and inhibition in different cell populations

Novel Applications

| Application | DREADD Used | Model System |
|-------------|-------------|--------------|
| Memory formation | hM3Dq | Hippocampal engram cells |
| Seizure suppression | hM4Di | Temporal lobe epilepsy |
| Feeding behavior | hM4Di | Arcuate nucleus |
| Sleep-wake control | hM3Dq/hM4Di | Hypothalamus |
| Mood regulation | hM3Dq | Prefrontal cortex |

Non-Neuronal Applications

Microglial Modulation

DREADDs have been adapted for non-neuronal cells[@peak2020]:

• P2X7-DREADD: Targeting microglia via P2X7 promoter
• CX3CR1-DREADD: Microglia-specific expression
• Effects: Modulating cytokine release, phagocytosis

Astrocytic Control

[Carson et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32621374/) demonstrated astrocyte-specific DREADDs:

• Calcium modulation: Controlling astrocytic signaling
• Metabolic regulation: Impacting neuronal support
• Neurovascular coupling: Modulating blood flow

Peripheral Targets

DREADDs have been applied beyond the CNS:

• Cardiac control: Modulating heart rate via vagal neurons
• Gastrointestinal: Controlling gut motility
• Immune system: Modulating peripheral immune cells

Clinical Trial Status

DREADDs remain in preclinical and translational research stages. The main clinical applications being explored include:

• Seizure control devices (though not DREADDs directly, the principle of chemogenetics)
• Targeted neuromodulation approaches that could complement or replace invasive DBS

Translation Challenges

| Challenge | Current Status | Potential Solutions |
|-----------|----------------|---------------------|
| BBB penetration | CNO poor, DCZ moderate | Novel ligand development |
| Long-term expression | Limited by immune response | Immunosuppression, newer vectors |
| Specificity | Off-target ligand effects | Engineered receptors |
| Clinical-grade ligand | Not available | Pharmaceutical development |

Near-Term Clinical Potential

While direct clinical DREADD therapy remains years away:

Experimental Protocols

Viral Delivery

Ligand Administration

| Route | Dose (CNO) | Dose (DCZ) | Onset |
|-------|------------|------------|-------|
| Intraperitoneal | 0.1-1 mg/kg | 0.01-0.1 mg/kg | 30-60 min |
| Subcutaneous | 0.1-1 mg/kg | 0.01-0.1 mg/kg | 30-60 min |
| Intravenous | 0.1-0.5 mg/kg | 0.01-0.05 mg/kg | 15-30 min |

Related Technologies

• [Chemogenetics](/technologies/chemogenetics)
• [Optogenetics](/technologies/optogenetics)
• [Deep Brain Stimulation](/therapeutics/deep-brain-stimulation)
• [Gene Therapy](/technologies/gene-therapy)
• [Parkinson's Disease Mechanisms](/diseases/parkinsons-disease)
• [Alzheimer's Disease Mechanisms](/diseases/alzheimers-disease)

References